Correction: Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass
Chih-Cheng Yang, Ladan Fazli, Salvatore Loguercio, Irina Zharkikh, Pedro Aza-Blanc, Martin E. Gleave, Dieter A. Wolf
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsProstate Cancer Treatment and Research · Cancer, Lipids, and Metabolism · PARP inhibition in cancer therapy
This article has been corrected: Oncotarget has completed its investigation of this paper. Our image forensic analysis found only one issue: a duplicated western blot panel in Figure 1. The corresponding author Dr. Dieter A. Wolf confirmed that in Figure 1E, the SRC panel is an accidental duplicate of the SRC panel in Figure 3D. The authors provided original, unmodified raw data for this experiment and the date stamp confirms its authenticity. The corrected Figure 1, which was produced using the original data, is shown below. The authors declare that this correction does not affect the results or conclusions of the paper.
Original article: Oncotarget. 2015; 6:22060–22071. 22060-22071. https://doi.org/10.18632/oncotarget.4279